SynthesisFrontiers in psychiatry2020
Expert Opinions and Consensus Recommendations for the Evaluation and Management of Insomnia in Clinical Practice: Joint Statements of Five Italian Scientific Societies.
Synthesis in Frontiers in psychiatry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 4 syntheses or guidelines pooled it, 75 citations in OpenAlex.
- Summary of the best evidence that cognitive behavioral therapy for insomnia improves sleep quality in patients with chronic insomnia.Frontiers in psychiatry · 2025Pooled it
- Guideline
- Insomnia evaluation and treatment during peripartum: a joint position paper from the European Insomnia Network task force "Sleep and Women," the Italian Marcè Society and international experts task force for perinatal mental health.Archives of women's mental health · 2022Pooled it
- International Expert Opinions and Recommendations on the Use of Melatonin in the Treatment of Insomnia and Circadian Sleep Disturbances in Adult Neuropsychiatric Disorders.Frontiers in psychiatry · 2021Pooled it
- Medical Professionals and Pharmacological Intervention for the Treatment of Insomnia: A Cross-Sectional Study.Sleep science (Sao Paulo, Brazil) · 2025Article
- Insomnia in seasonal affective disorder: considering the use of benzodiazepines with a focus on lormetazepam.Frontiers in psychiatry · 2025Review
- Failure to reduce benzodiazepine prescriptions through the implementation of a psychological intervention for insomnia in an Italian mental health service.European journal of clinical pharmacology · 2024Article
- Assessment and management of chronic insomnia disorder: an algorithm for primary care physicians.BMC primary care · 2024Article
- Is there a better way to wean chronic benzodiazepine receptor agonists use by substituting a DORA (and starting CBT-I)?Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2024Article
- Prescribing and deprescribing guidance for benzodiazepine and benzodiazepine receptor agonist use in adults with depression, anxiety, and insomnia: an international scoping review.EClinicalMedicine · 2024Article
- Chronic Insomnia Disorder across Europe: Expert Opinion on Challenges and Opportunities to Improve Care.Healthcare (Basel, Switzerland) · 2023Review
- Insomnia among Cancer Patients in the Real World: Optimising Treatments and Tailored Therapies.International journal of environmental research and public health · 2023Review
- Long-term use of benzodiazepines in chronic insomnia: a European perspective.Frontiers in psychiatry · 2023Article
- Possible Application of Melatonin in Long COVID.Biomolecules · 2022Review
- Insomnia in primary care: a survey conducted on Italian patients older than 50 years-results from the "Sonno e Salute" study.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2022Observational
- Sleepless nights mean worse metabolism: a link to cardiovascular risk in older women.European geriatric medicine · 2022Article
- Pharmacotherapeutic management of insomnia and effects on sleep processes, neural plasticity, and brain systems modulating stress: A narrative review.Frontiers in neuroscience · 2022Review
- Melatonin's Benefits and Risks as a Therapy for Sleep Disturbances in the Elderly: Current Insights.Nature and science of sleep · 2022Review
- Efficacy of Prolonged-Release Melatonin 2 mg (PRM 2 mg) Prescribed for Insomnia in Hospitalized Patients for COVID-19: A Retrospective Observational Study.Journal of clinical medicine · 2021Article
- Melatonin: From Neurobiology to Treatment.Brain sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 11 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInsomnia is the most commonly reported sleep problem in industrialized countries worldwide being present in about 36.8% of the general population. In Italy, such a percentage seems to be even higher. Although insomnia can be an independent disorder, it is most frequently observed as a comorbid condition and may precipitate, exacerbate, or prolong a broad range of comorbid conditions including physical and mental illnesses. Evaluating and targeting insomnia in the Italian clinical practice should be a priority.
methodsThe present expert options and recommendations development process was based on the RAND/UCLA Appropriateness Method for conceptualizing, designing, and carrying out the appropriateness of procedures for the diagnosis and treatment. Only available options in Italy were taken into considerations.
resultsWe evaluated 12 international guidelines and 12 most recent systematic reviews for insomnia evaluation and treatment produced in the last 10 years.
conclusionsOur findings suggested that symptoms of insomnia must always be assessed in the Italian clinical practice by evaluating nocturnal and daytime symptoms, comorbid conditions and lifestyle. In a patient with chronic insomnia with and without comorbidity, insomnia treatment should be always initiated. CBT-Insomnia therapy should be the first option accordingly to availability. The choice of the drug should be based on different factors such as type of insomnia, age, comorbidities, and potential side effects. Melatonin 2 mg prolonged release should be the first choice in subjects >55 years. If the choice would be a Z-drug or a short-acting benzodiazepine (in subjects <65 years old) or a sedating antidepressant, the use should be in the short term (≤4 weeks) and then proceeds to tapering under clinical monitoring.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.